Wegovy Weight Loss Results: Timeline & Averages

Wegovy weight loss results average about 15% of total body weight over roughly 68 weeks of treatment, based on the STEP-1 clinical trial. Weight comes off gradually: the first 16 to 20 weeks are dose titration with modest early loss, the middle months are usually steepest, and loss flattens toward a plateau near 68 weeks. Individual results vary widely and depend on reaching and staying on the full dose, adherence, and diet and activity.

Wegovy is the brand name for semaglutide 2.4 mg once weekly, a GLP-1 medication that is FDA-approved for chronic weight management. It works mainly by reducing appetite, which makes it easier to eat less without the constant hunger that usually derails a calorie deficit. If you want the underlying biology, see how semaglutide works for weight loss. This article focuses on what the numbers actually look like and when to expect them.

What are the average Wegovy weight loss results?

In the STEP-1 trial, adults with overweight or obesity who took semaglutide 2.4 mg alongside lifestyle changes lost an average of about 15% of their starting body weight over 68 weeks. The precise figure was 14.9%. For someone starting at 220 pounds, that is roughly 33 pounds on average.

Averages hide a lot of spread. Roughly a third of participants lost 20% or more of their body weight, a response closer to what some people see with bariatric surgery. Others lost less. The placebo group, who also received lifestyle counseling, lost only a few percent, which tells us most of the effect comes from the drug plus lifestyle rather than lifestyle alone. For how Wegovy stacks up against other options, compare GLP-1 weight loss results by drug.

Wegovy weight loss results by timeline

Weight does not come off in a straight line. The dose is deliberately increased slowly to reduce side effects, so the early weeks are more about getting your body used to the medication than about big scale drops. The table below shows a typical pattern. Treat the loss figures as rough averages, not promises.

Timeline	Phase	Typical cumulative loss
Month 1 to 4	Dose titration (0.25 mg building toward 2.4 mg)	Modest early loss, often a few percent
Month 5 to 9	Full maintenance dose, steepest period	Loss usually accelerates here
Month 12 and beyond	Approaching plateau near 68 weeks	Around 15% on average, then flattening

The first 16 to 20 weeks are titration, stepping from a 0.25 mg starting dose up to the 2.4 mg maintenance dose. Do not expect dramatic results during this window; it is normal for the scale to move slowly. Loss is typically steepest in the middle months once you are on the full dose, and it flattens toward a plateau at around 68 weeks, which lands roughly 12 to 17 months after starting. For a broader view across the class, see the GLP-1 weight loss timeline.

What determines how much weight loss you get on Wegovy

Because the range is so wide, it helps to know what pushes results toward the higher or lower end.

• Reaching and staying on the full dose. The average results come from the 2.4 mg maintenance dose. People who cannot tolerate the full dose or who stop early tend to lose less. Your clinician sets the schedule; see Wegovy dosage for how titration works. Do not exceed 2.4 mg.
• Adherence. Wegovy is a once-weekly injection. Missing doses or long gaps interrupts appetite suppression and slows progress.
• Diet and activity. The trial paired the drug with lifestyle changes. The medication makes a calorie deficit easier to sustain, but the deficit still has to happen.
• Side effects. Nausea and other gut symptoms can affect tolerance and dosing. See Wegovy side effects for what is common and how it is usually managed.

Setting expectations before you start matters. Many people anchor to the biggest social media transformations rather than the average. For a grounded framework, read realistic weight loss goals on GLP-1.

What happens after you stop Wegovy

This is the part that surprises people. Weight is often partly regained after stopping, because the medication suppresses appetite rather than permanently resetting it. When appetite returns to its previous level, calorie intake tends to climb back up, and so does weight for many people.

That does not mean the results were wasted. Maintaining them depends on continued treatment or on the habits built while on the drug: eating patterns, activity, sleep, and portion awareness. Some people stay on a maintenance approach long term, while others use the window of easier appetite control to lock in routines. This is a decision to make with a clinician based on your health, not a one-size-fits-all rule.

Protecting muscle while you lose weight

Rapid or large weight loss from any method includes some loss of muscle along with fat. Two habits help preserve muscle during Wegovy treatment: eating adequate protein and doing resistance training. Keeping muscle is not only about appearance; it supports metabolism and day-to-day strength, which makes it easier to keep weight off later.

How Wegovy compares to Zepbound

Wegovy is often compared to Zepbound (tirzepatide), a newer medication that works on two gut hormone pathways instead of one. Head-to-head, tirzepatide has produced larger average losses in trials, but the right choice depends on your health profile, tolerance, insurance, and access, not on the headline number alone. See Wegovy vs Zepbound for a fuller comparison.